£110.93

Horizons in Cancer Research: Volume 72

Price data last checked 9 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 2 months ago.

£111 today · all-time low £109 (May 2026) · usually £113

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 82 days · 82 data points (no recent data)

Historical
Generating forecast…
£113.25 £108.42 £109.47 £110.53 £111.58 £112.64 £113.69 26 April 2026 16 May 2026 05 June 2026 25 June 2026 16 July 2026

Price Distribution

Price distribution over 82 days • 4 price levels

Days at Price
Current Price
8 days 24 days 16 days · current 34 days 0 9 17 26 34 £109 £110 £111 £113 Days at Price

Price Analysis

Most common price: £113 (34 days, 41.5%)

Price range: £109 - £113

Price levels: 4 different prices over 82 days

Description

Volume 72 discusses the Ewing's sarcoma family of tumours, including classic Ewing's sarcoma of the bone, extraskeletal Ewing's sarcoma and malignant peripheral primitive neuroectodermal tumour of both bone and soft tissue. The following chapter discusses Primary Ewing's sarcoma of the base of the tongue, particularly its diagnosis and treatment. Additionally, the authors examine dual proteasome and histone deacetylase6 inhibitor, dual MDM2 and histone deacetylase inhibitor, and dual bromodomain-containing protein 4 and histone deacetylase inhibitor. The authors go on to examine the genes and proteins involved in mitosis that are proposed as candidates for biomarkers in different types of cancer (colon, lung, prostate, breast and ovarian, among others). The penultimate chapter reviews the published evidence of aromatase inhibitors in breast cancer risk reduction. The recommended patient populations for the use of aromatase inhibitors, expected benefits, adverse effects and monitoring parameters are addressed. The transcription factor and chromatin structure-related aspects of cancer treatment are the focus of the final chapter.

Product Specifications

Barcode

No barcode data available